IL-12 pretreatments enhance IFN-α-induced Janus kinase-STAT signaling and potentiate the antitumor effects of IFN-α in a murine model of malignant melanoma

Journal of Immunology

Volumn 172, Issue 12, 2004, Pages 7368-7376

  Lesinski, Gregory B ^a   Badgwell, Brian ^a   Zimmerer, Jason ^a   Crespin, Tim ^b   Hu, Yan ^a   Abood, Gerard ^a   Carson III, William E ^a,c  

^a OHIO STATE UNIVERSITY   (United States)

^b Primetrics Inc   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; JANUS KINASE; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT GAMMA INTERFERON; STAT PROTEIN;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR MODEL;

EID: 2942555182     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.172.12.7368     Document Type: Article

References (59)

1. Atkins, M. B. 1998, Immunotherapy and experimental approaches for metastatic melanoma. Hematol Oncol. Clin. North Am. 12:877.
2. Green, R. J., and L. M. Schuchter. 1998. Systemic treatment of metastatic melanoma with chemotherapy. Hematol. Oncol. Clin. North Am. 12:863.
3. Legha, S. S., S. Ring, O. Eton, A. Bedikian, A. C. Buzaid, C. Plager, and N. Papadopoulos. 1998. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon α, and interleukin-2 for patients with metastatic melanoma. J. Clin. Oncol. 16:1752.
4. Hemmila, M. R., and A. E. Chang. 1999. Clinical implications of the new biology in the development of melanoma vaccines. J. Surg. Oncol. 70(Suppl.):263.
5. McMasters, K. M., V. K. Sondak, M. T. Lotze, and M. I. Ross. 1999. Recent advances in melanoma staging and therapy. Ann. Surg. Oncol. 6:467.
6. Kirkwood, J. M., J. G. Ibrahim, V. K. Sondak, M. S. Ernstoff, and M. Ross. 2002. Interferon α-2a for melanoma metastases. Lancet 359:978.
7. Belardelli, F., M. Ferrantini, E. Proietti, and J. M. Kirkwood. 2002. Interferon-α in tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13:119.
8. Balch, C. M. 1998. Biologic therapy. In Biologic Therapy. Quality Medical Publishing, St. Louis, p. 419.
9. Legha, S. S. 1986. Interferons in the treatment of malignant melanoma: a review of recent trials. Cancer 57:1675.
10. Kirkwood, J. M., M. H. Strawderman, M. S. Ernstoff, T. J. Smith, E. C. Borden, and R. H. Blum. 1996. Interferon α-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol. 14:7.
11. Lens, M. B., and M. Dawes. 2002. Interferon α therapy for malignant melanoma: a systematic review of randomized controlled trials. J. Clin. Oncol. 20:1818.
12. Kirkwood, J. M., J. G. Ibrahim, V. K. Sondak, J. Richards, L. E. Flaherty, M. S. Ernstoff, T. J. Smith, U. Rao, M. Steele, and R. H. Blum. 2000. High- and low-dose interferon α-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J. Clin. Oncol. 18:2444.
13. Creagan, E. T., R. J. Dalton, D. L. Ahmann, S. H. Jung, R. F. Morton, R. M. Langdon, Jr., J. Kugler, and L. J. Rodrigue. 1995. Randomized, surgical adjuvant clinical trial of recombinant interferon α-2a in selected patients with malignant melanoma. J. Clin. Oncol. 13:2776.
14. Kirkwood, J. M., J. G. Ibrahim, J. A. Sosman, V. K. Sondak, S. S. Agarwala, M. S. Ernstoff, and U. Rao. 2001. High-dose interferon α-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J. Clin. Oncol. 19:2370.
15. Agarwala, S. S., and J. M. Kirkwood. 1995. Potential uses of interferon α2 as adjuvant therapy in cancer. Ann. Surg. Oncol. 2:365.
16. Schindler, C., K. Shuai, V. R. Prezioso, and J. E. Darnell, Jr. 1992. Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor. Science 257:809.
17. Levy, D. E., D. J. Lew, T. Decker, D. S. Kessler, and J. E. Darnell, Jr. 1990. Synergistic interaction between interferon-α and intefferon-γ through induced synthesis of one subunit of the transcription factor ISGF3. EMBO J. 9:1105.
18. Improta, T., R. Pine, and L. M. Pfeffer. 1992. Interferon-γ potentiates the antiviral activity and the expression of interferon-stimulated genes induced by interferon-α in U937 cells. J. Interferon Res. 12:87.
19. Hannigan, G. E., E. N. Fish, and B. R. Williams. 1984. Modulation of human interferon-α receptor expression by human interferon-γ. J. Riol. Chem. 259:8084.
20. Lehtonen, A., S. Matikainen, and I. Julkunen. 1997. Interferons up-regulate STAT1, STAT2, and IRF family transcription factor gene expression in human peripheral blood mononuclear cells and macrophages. J. Immunol. 159:794.
21. Trinchieri, G. 1994. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 84:4008.
22. Lesinski, G. B., M. Anghelina, J. Zimmerer, T. Bakalakos, B. Badgwell, R. Parihar, Y. Hu, B. Becknell, G. Abood, A. RayChaudhury, et al. 2003. The anti-tumor effects of interferon-α are abrogated in a STAT1-deficient mouse. J. Clin. Invest. 112:170.
23. Fallarino, F., and T. F. Gajewski. 1999. Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1. J. Immunol. 163:4109.
24. Bromberg, J. F., C. M. Horvath, Z. Wen, R. D. Schreiber, and J. E. Darnell, Jr. 1996. Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon a and interferon γ. Proc. Natl. Acad. Sci. USA 93:7673.
25. Kaplan, D. H., V. Shankaran, A. S. Dighe, E. Stockert, M. Aguet, L. J. Old, and R. D. Schreiber. 1998. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA 95:7556.
26. Carson, W. E., M. E. Ross, R. A. Baiocchi, M. J. Marien, N. Boiani, K. Grabstein, and M. A. Caligiuri. 1995. Endogenous production of interleukin 15 by activated human monocytes is critical for optimal production of interferon-γ by natural killer cells in vitro. J. Clin. Invest. 96:2578.
27. Carson, W. E., M. J. Lindemann, R. Baiocchi, M. Linett, J. C. Tan, C. C. Chou, S. Narula, and M. A. Caligiuri. 1995. The functional characterization of interleukin-10 receptor expression on human natural killer cells. Blood 85:3577.
28. Fleisher, T. A., S. E. Dorman, J. A. Anderson, M. Vail, M. R. Brown, and S. M. Holland. 1999. Detection of intracellular phosphorylated STAT-1 by flow cytometry. Clin. Immunol. 90:425.
29. Sadowski, H. B., K. Shuai, J. E. Damell, Jr., and M. Z. Gilman. 1993. A common nuclear signal transduction pathway activated by growth factor and cytokine receptors. Science 261:1739.
30. Carson, W. E. 1998. Interferon-α-induced activation of signal transducer and activator of transcription proteins in malignant melanoma. Clin. Cancer Res. 4:2219.
31. Fehniger, T. A., M. H. Shah, M. J. Turner, J. B. VanDeusen, S. P. Whitman, M. A. Cooper, K. Suzuki, M. Wechser, F. Goodsaid, and M. A. Caligiuri. 1999. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J. Immunol. 162:4511.
32. Tokuhiro, S., R. Yamada, X. Chang, A. Suzuki, Y. Kochi, T. Sawada, M. Suzuki, M. Nagasaki, M. Ohtsuki, M. Ono, et al. 2003. An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. Nat. Genet. 35:341.
33. Smith, J. K., A. A. Siddiqui, G. A. Krishnaswamy, R. Dykes, S. L. Berk, M. Magee, W. Joyner, and J. Cummins. 1999. Oral use of interferon-α stimulates ISG-15 transcription and production by human buccal epithelial cells. J. Interferon Cytokine Res. 19:923.
34. Taylor, J. L., J. D'Cunha, P. Tom, W. J. O'Brien, and E. C. Borden. 1996. Production of ISG-15, an interferon-inducible protein, in human corneal cells. J. Interferon Cytokine Res. 16:937.
35. Au, W. C., N. B. Raj, R. Pine, and P. M. Pitha. 1992. Distinct activation of murine interferon-α promoter region by IRF-1/ISFG-2 and virus infection. Nucleic Acids Res. 20:2877.
36. D'Cunha, J., S. Ramanujam, R. J. Wagner, P. L. Witt, E. Knight, Jr., and E. C. Borden. 1996. In vitro and in vivo secretion of human ISG15, an IFN-induced immunomodulatory cytokine. J. Immunol. 157:4100.
37. D'Cunha, J., E. Knight, Jr., A. L. Haas, R. L. Truitt, and E. C. Borden. 1996. Immunoregulatory properties of ISG15, an interferon-induced cytokine. Proc. Natl. Acad. Sci. USA 93:211.
38. Fleischmann, C. M., G. J. Stanton, and W. R. Fleischmann, Jr. 1996. Enhanced in vivo sensitivity of in vitro interferon-treated B16 melanoma cells to CD8 cells and activated macrophages. J. Interferon Cytokine Res. 16:805.
39. Carson, W. E., H. Yu, J. Dierksheide, K. Pfeffer, P. Bouchard, R. Clark, J. Durbin, A. S. Baldwin, J. Peschon, P. R. Johnson, G. Ku, et al. 1999. A fatal cytokine-induced systemic inflammatory response reveals a critical role for NK cells. J. Immunol. 162:4943.
40. Carson, W. E., M. Anghelina, J. Dierksheide, S. Dierksheide, P. Sundaram, and P. Triozzi. 1999. Therapy of melanoma with IL-12 and interferon-α. Eur. J. Cancer 35(Suppl. 5):4.
41. Kakuta, S., Y. Tagawa, S. Shibata, M. Nanno, and Y. Iwakura. 2002. Inhibition of B16 melanoma experimental metastasis by interferon-γ through direct inhibition of cell proliferation and activation of antitumour host mechanisms. Immunology 105:92.
42. Leonard, J. P., M. L. Sherman, G. L. Fisher, L. J. Buchanan, G. Larsen, M. B. Atkins, J. A. Sosman, J. P. Dutcher, N. J. Vogelzang, and J. L. Ryan. 1997. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-γ production. Blood 90:2541.
43. Atkins, M. B., M. J. Robertson, M. Gordon, M. T. Lotze, M. DeCoste, J. S. DuBois, J. Ritz, A. B. Sandler, H. D. Edington, P. D. Garzone, et al. 1997. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin. Cancer Res. 3:409.
44. Nguyen, K. B., W. T. Watford, R. Salomon, S. R. Hofmann, G. C. Pien, A. Morinobu, M. Gadina, J. J. O'Shea, and C. A. Biron. 2002. Critical role for STAT4 activation by type 1 interferons in the interferon-γ response to viral infection. Science 297:2063.
45. Brunda, M. J., L. Luistro, R. R. Warrier, R. B. Wright, B. R. Hubbard, M. Murphy, S. F. Wolf, and M. K. Gately. 1993. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178:1223.
46. Tannenbaum, C. S., N. Wicker, D. Armstrong, R. Tubbs, J. Finke, R. M. Bukowski, and T. A. Hamilton. 1996. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J. Immunol. 156:693.
47. Su, W., T. Ito, T. Oyama, T. Kitagawa, T. Yamori, H. Fujiwara, and H. Matsuda. 2001. The direct effect of IL-12 on tumor cells: IL-12 acts directly on tumor cells to activate NF-κB and enhance IFN-γ-mediated STAT1 phosphorylation. Biochem. Biophys. Res. Commun. 280:503.
48. Hu, X., C. Herrero, W. P. Li, T. T. Antoniv, E. Falck-Pedersen, A. E. Koch, J. M. Woods, G. K. Haines, and L. B. Ivashkiv. 2002. Sensitization of IFN-γ Jak-STAT signaling during macrophage activation. Nat. Immunol. 3:859.
49. Mendiratta, S. K., A. Quezada, M. Matar, N. M. Thull, J. S. Bishop, J. L. Nordstrom, and F. Pericle. 2000. Combination of interleukin 12 and interferon a gene therapy induces a synergistic antitumor response against colon and renal cell carcinoma. Hum. Gene Ther. 11:1851.
50. Li, D., J. W. Zeiders, S. Liu, M. Guo, Y. Xu, J. S. Bishop, and B. W. O'Malley, Jr. 2001. Combination nonviral cytokine gene therapy for head and neck cancer. Laryngoscope 111:815.
51. Dabrowska, A., A. Giermasz, J. Golab, and M. Jakobisiak. 2001. Potentiated antitumor effects of interleukin 12 and interferon a against B 16F10 melanoma in mice. Neoplasma 48:358.
52. Flieger, D., U. Spengler, I. Beier, R. Kleinschmidt, T. Sauerbruch, and I. G. Schmidt-Wolf. 2000. Augmentation of 17-1A-induced antibody-dependent cellular cytotoxicity by the triple cytokine combination of interferon-α, interleukin-2, and interleukin-12. J. Immunother. 23:480.
53. Ernstoff, M. S., S. Nair, R. R. Bahnson, L. M. Miketic, B. Banner, W. Gooding, R. Day, T. Whiteside, T. Hakala, and J. M. Kirkwood. 1990. A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon γ and recombinant interferon a in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 8:1637.
54. Creagan, E. T., C. L. Loprinzi, D. L. Ahmann, and D. J. Schaid. 1988. A phase I-II trial of the combination of recombinant leukocyte A interferon and recombinant human interferon-γ in patients with metastatic malignant melanoma. Cancer 62:2472.
55. Osanto, S., R. Jansen, A. M. Naipal, J. W. Gratama, A. van Leeuwen, and F. J. Cleton. 1989. In vivo effects of combination treatment with recombinant interferon-γ and -α in metastatic melanoma. Int. J. Cancer. 43:1001.
56. Opalka, B., U. B. Wandl, R. Becher, O. Kloke, M. Nagel-Hiemke, T. Moritz, U. Beer, S. Seeber, and N. Niederie. 1991. Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon α-2b alone or in combination with interferon γ. Blood 78:2188.
57. Wandl, U. B., O. Kloke, M. Nagel-Hiemke, T. Moritz, R. Becher, B. Opalka, W. Holtkamp, H. Bartels, S. Seeber, and N. Niederle. 1992. Combination therapy with interferon α-2b plus low-dose interferon γ in pretreated patients with Ph-positive chronic myelogenous leukaemia. Br. J. Haematol. 81:516.
58. Kurzrock, R., M. G. Rosenblum, J. R. Quesada, S. A. Sherwin, L. M. Itri, and J. U. Gutterman. 1986. Phase I study of a combination of recombinant interferon-α and recombinant interferon-γ in cancer patients. J. Clin. Oncol. 4:1677.
59. Gollob, J. A., J. W. Mier, K. Veenstra, D. F. McDermott, D. Clancy, M. Clancy, and M. B. Atkins. 2000. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-γ induction is associated with clinical response. Clin. Cancer Res. 6:1678.